NICE rebuffs Multaq

The U.K.'s NICE issued a preliminary appraisal recommending against the use of Multaq dronedarone from sanofi-aventis Group (Euronext:SAN; NYSE:SNY) to treat atrial fibrillation. The agency said Multaq appeared to be less effective for AF recurrence than other anti-arrhythmic drugs, such as amiodarone. It also said Multaq could not be considered a cost-effective use of NHS resources. ...